The global oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030, up from USD 10.5 billion in 2025, growing at a robust compound annual growth rate (CAGR) of 18.6% during the forecast period. The market growth is primarily driven by the rising adoption of oligonucleotide-based therapeutics, increasing demand for personalized medicine, technological advancements, and ongoing investment in research and development (R&D).
Oligonucleotides, short sequences of nucleotides, are fundamental tools in genetic research, molecular diagnostics, and therapeutic applications. They are extensively used in antisense therapies, RNA interference (RNAi), and gene editing, offering significant potential for treating rare and complex diseases. The expanding applications of mRNA vaccines, CRISPR-based therapies, and nucleic acid-based diagnostics are further propelling demand across pharmaceutical and biopharmaceutical sectors.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=200829350
Market Drivers: Innovation in Therapeutics and Research Applications
The growth of the oligonucleotide synthesis market is closely linked to the increasing prevalence of genetic disorders, cancer, and chronic diseases, which has fueled the development of targeted therapies and precision medicines. Additionally, the growing popularity of gene therapy and personalized treatment approaches is driving pharmaceutical companies to invest heavily in oligonucleotide synthesis capabilities.
Technological advancements, including automated high-throughput synthesizers, modified nucleotides, and high-fidelity synthesis techniques, are enhancing efficiency, scalability, and quality of oligonucleotide products. Furthermore, collaborations between research institutions and commercial players are accelerating the development of novel oligonucleotide therapeutics for previously untreatable conditions.
Competitive Landscape and Key Players
The oligonucleotide synthesis market is highly competitive, with leading companies pursuing strategies such as product launches, acquisitions, strategic partnerships, collaborations, and geographic expansions. Prominent market players include Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai Lifesciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US).
Simultaneously, the oligonucleotide therapeutics market features major players such as Biogen (US), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland).
Danaher Corporation (US)
Danaher, through subsidiaries Integrated DNA Technologies (IDT) and Cytiva, offers a comprehensive portfolio of pre-designed and custom oligonucleotide probes, primers, antisense oligonucleotides (ASOs), reagents, consumables, and synthesis equipment. The company operates in over 50 countries across North America, Europe, Asia Pacific, and the Middle East & Africa. In 2023, IDT opened a state-of-the-art therapeutic oligonucleotide manufacturing facility in Coralville, Iowa, designed to produce reagents for cGMP cell and gene therapy, including single-guide RNAs and HDR donor oligonucleotides. The facility features eight ISO cleanrooms, purification suites, analytical labs, and shell space for future expansions, reflecting Danaher’s commitment to innovation and market growth.
Thermo Fisher Scientific (US)
Thermo Fisher holds a leading position in the market due to its broad product portfolio, including custom and pre-designed primers, probes, DNA and RNA oligos, reagents, and consumables. The company employs both organic and inorganic growth strategies, such as collaborations with academic institutions. Notably, in 2021, Thermo Fisher partnered with the University of Sheffield to develop workflows for characterizing complex oligonucleotide and mRNA products. With operations in over 50 countries, Thermo Fisher’s global reach significantly strengthens its market presence.
Biogen (US)
Biogen is a key player in the oligonucleotide therapeutics market, benefiting from the FDA accelerated approval of QALSODY (Tofersen) for amyotrophic lateral sclerosis (ALS) and the widespread adoption of Spinzara, an oligonucleotide-based drug. Biogen operates an oligonucleotide synthesis manufacturing (OSM) facility in North Carolina for producing antisense oligonucleotide drugs and candidates in development. In February 2025, Biogen partnered with Stoke Therapeutics, Inc. to develop Zorevunersen, an investigational ASO for treating Dravet syndrome, showcasing its strategy of expansion and collaboration.
Market Structure and Opportunities
The oligonucleotide synthesis market is moderately consolidated, with the top five players collectively holding approximately 50–60% of total market share. Danaher and Thermo Fisher dominate due to their diverse product portfolios and global operations, followed by Merck KGaA, LGC Limited, and Eurofins Scientific. The remaining 40–50% is held by regional and emerging players, creating room for innovation and growth, particularly in Asia Pacific and Latin American markets, which are witnessing increasing demand from pharmaceutical and biopharmaceutical companies.
In the oligonucleotide therapeutics segment, the market is more concentrated, with the top five companies accounting for 85–90% of market share. Leading firms include Alnylam Pharmaceuticals, Sarepta Therapeutics, Novartis AG, Biogen, and Astellas Pharma. Their dominance is supported by first-in-class product launches, strategic partnerships, and growing demand for personalized medicine, while regional and emerging companies hold 10–15% of the market, contributing to scientific innovation and niche therapeutic solutions.
Conclusion
The global oligonucleotide synthesis market is poised for significant growth through 2030, driven by technological innovation, expanding applications in gene therapy and personalized medicine, and increasing demand for high-quality oligonucleotide products. Leading players, including Danaher, Thermo Fisher, and Biogen, are strengthening their market positions through R&D investment, facility expansions, collaborations, and strategic partnerships, while emerging players continue to contribute to innovation and niche therapeutic development.Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=200829350
